Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
senatibrutinib
- Development stage
- Unknown
- Lead developer
- Everest Medicines
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Senatibrutinib (XNW 1011) is a potent, highly selective, and irreversible small-molecule inhibitor of Bruton's tyrosine kinase (BTK). Developed by Sinovent (Suzhou Sinoway Pharmaceutical Technology), it is designed to treat various B-cell malignancies by blocking the B-cell receptor (BCR) signaling pathway, which is essential for the survival and proliferation of malignant B cells. By covalently binding to the BTK enzyme, senatibrutinib inhibits its activity, leading to decreased B-cell activation and tumor growth. It is currently being evaluated in clinical trials for indications including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), and Waldenström macroglobulinemia. Its high selectivity is intended to minimize off-target effects and improve the safety profile compared to first-generation BTK inhibitors.
- Other names
- senatibrutinib
02
Targets
BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on senatibrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on senatibrutinib.